Document Detail

Genetic prognostic and predictive markers in colorectal cancer.
MedLine Citation:
PMID:  19536109     Owner:  NLM     Status:  MEDLINE    
Despite many studies of the likely survival outcome of individual patients with colorectal cancer, our knowledge of this subject remains poor. Until recently, we had virtually no understanding of individual responses to therapy, but the discovery of the KRAS mutation as a marker of probable failure of epidermal growth factor receptor (EGFR)-targeted therapy is a first step in the tailoring of treatment to the individual. With the application of molecular analyses, as well as the ability to perform high-throughput screens, there has been an explosive increase in the number of markers thought to be associated with prognosis and treatment outcome in this disease. In this Review, we attempt to summarize the sometimes confusing findings, and critically assess those markers already in the public domain.
Axel Walther; Elaine Johnstone; Charles Swanton; Rachel Midgley; Ian Tomlinson; David Kerr
Related Documents :
19774209 - Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.
18460519 - Targeting growth factors in lung cancer.
15949939 - Shedding light on adam metalloproteinases.
21304039 - Rhabdomyolysis in a prostate cancer patient taking ketoconazole and simvastatin: case r...
18406819 - Insulin receptor what role in breast cancer?
19817649 - Hypoxia related growth factors and p53 in preoperative sera from patients with colorect...
7605169 - Asbestos contamination in paraffin tissue blocks.
20081809 - Cd133 expression predicts for non-response to chemotherapy in colorectal cancer.
21414479 - Principles and strategies for developing network models in cancer.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2009-06-18
Journal Detail:
Title:  Nature reviews. Cancer     Volume:  9     ISSN:  1474-1768     ISO Abbreviation:  Nat. Rev. Cancer     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-06-24     Completed Date:  2009-07-08     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  101124168     Medline TA:  Nat Rev Cancer     Country:  England    
Other Details:
Languages:  eng     Pagination:  489-99     Citation Subset:  IM    
Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, SM2 5PT, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Camptothecin / analogs & derivatives,  therapeutic use
Chromosomes, Human, Pair 18
Colorectal Neoplasms / drug therapy,  genetics*,  mortality*
Deoxycytidine / analogs & derivatives,  therapeutic use
Fluorouracil / analogs & derivatives,  therapeutic use
Gene Expression Profiling
Genes, APC
Genes, p53
Genomic Instability
Microsatellite Instability
Organoplatinum Compounds / therapeutic use
Proto-Oncogene Proteins / genetics
Proto-Oncogene Proteins B-raf / genetics
Tumor Markers, Biological
beta Catenin / metabolism
ras Proteins / genetics
Reg. No./Substance:
0/KRAS protein, human; 0/Organoplatinum Compounds; 0/Proto-Oncogene Proteins; 0/Tumor Markers, Biological; 0/beta Catenin; 51-21-8/Fluorouracil; 63121-00-6/oxaliplatin; 6804DJ8Z9U/capecitabine; 7673326042/irinotecan; 7689-03-4/Camptothecin; 951-77-9/Deoxycytidine; EC protein, human; EC Proteins B-raf; EC Proteins
Erratum In:
Nat Rev Cancer. 2011 Apr;11(4):309

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cancer prevention research - then and now.
Next Document:  Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astrogli...